A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

OBJECTIVES: Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We e...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Skin Cancer
Главные авторы: Odom, Dawn, Mladsi, Deirdre, Purser, Molly, Kaye, James A., Palaka, Eirini, Charter, Alina, Jensen, Jo Annah, Sellami, Dalila
Формат: Artigo
Язык:Inglês
Опубликовано: Hindawi 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457749/
https://ncbi.nlm.nih.gov/pubmed/28607774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6121760
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы